Potential Clinical Applications for Human Pluripotent Stem Cell-Derived Blood Components
The ability of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) to divide indefinitely without losing pluripotency and to theoretically differentiate into any cell type in the body makes them highly attractive cell sources for large scale regenerative medicine purposes....
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.4061/2011/273076 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850167067084324864 |
|---|---|
| author | Erin A. Kimbrel Shi-Jiang Lu |
| author_facet | Erin A. Kimbrel Shi-Jiang Lu |
| author_sort | Erin A. Kimbrel |
| collection | DOAJ |
| description | The ability of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) to divide indefinitely without losing pluripotency and to theoretically differentiate into any cell type in the body makes them highly attractive cell sources for large scale regenerative medicine purposes. The current use of adult stem cell-derived products in hematologic intervention sets an important precedent and provides a guide for developing hESC/iPSC based therapies for the blood system. In this review, we highlight biological functions of mature cells of the blood, clinical conditions requiring the transfusion or stimulation of these cells, and the potential for hESC/iPSC-derivatives to serve as functional replacements. Many researchers have already been able to differentiate hESCs and/or iPSCs into specific mature blood cell types. For example, hESC-derived red blood cells and platelets are functional in tasks such as oxygen delivery and blood clotting, respectively and may be able to serve as substitutes for their donor-derived counterparts in emergencies. hESC-derived dendritic cells are functional in antigen-presentation and may be used as off-the-shelf vaccine therapies to stimulate antigen-specific immune responses against cancer cells. However, in vitro differentiation systems used to generate these cells will need further optimization before hESC/iPSC-derived blood components can be used clinically. |
| format | Article |
| id | doaj-art-db67cc6daf38496a92805faaa0a26c53 |
| institution | OA Journals |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-db67cc6daf38496a92805faaa0a26c532025-08-20T02:21:17ZengWileyStem Cells International1687-966X1687-96782011-01-01201110.4061/2011/273076273076Potential Clinical Applications for Human Pluripotent Stem Cell-Derived Blood ComponentsErin A. Kimbrel0Shi-Jiang Lu1Stem Cell & Regenerative Medicine International, 33 Locke Drive, Marlborough, MA 01752, USAStem Cell & Regenerative Medicine International, 33 Locke Drive, Marlborough, MA 01752, USAThe ability of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) to divide indefinitely without losing pluripotency and to theoretically differentiate into any cell type in the body makes them highly attractive cell sources for large scale regenerative medicine purposes. The current use of adult stem cell-derived products in hematologic intervention sets an important precedent and provides a guide for developing hESC/iPSC based therapies for the blood system. In this review, we highlight biological functions of mature cells of the blood, clinical conditions requiring the transfusion or stimulation of these cells, and the potential for hESC/iPSC-derivatives to serve as functional replacements. Many researchers have already been able to differentiate hESCs and/or iPSCs into specific mature blood cell types. For example, hESC-derived red blood cells and platelets are functional in tasks such as oxygen delivery and blood clotting, respectively and may be able to serve as substitutes for their donor-derived counterparts in emergencies. hESC-derived dendritic cells are functional in antigen-presentation and may be used as off-the-shelf vaccine therapies to stimulate antigen-specific immune responses against cancer cells. However, in vitro differentiation systems used to generate these cells will need further optimization before hESC/iPSC-derived blood components can be used clinically.http://dx.doi.org/10.4061/2011/273076 |
| spellingShingle | Erin A. Kimbrel Shi-Jiang Lu Potential Clinical Applications for Human Pluripotent Stem Cell-Derived Blood Components Stem Cells International |
| title | Potential Clinical Applications for Human Pluripotent Stem Cell-Derived Blood Components |
| title_full | Potential Clinical Applications for Human Pluripotent Stem Cell-Derived Blood Components |
| title_fullStr | Potential Clinical Applications for Human Pluripotent Stem Cell-Derived Blood Components |
| title_full_unstemmed | Potential Clinical Applications for Human Pluripotent Stem Cell-Derived Blood Components |
| title_short | Potential Clinical Applications for Human Pluripotent Stem Cell-Derived Blood Components |
| title_sort | potential clinical applications for human pluripotent stem cell derived blood components |
| url | http://dx.doi.org/10.4061/2011/273076 |
| work_keys_str_mv | AT erinakimbrel potentialclinicalapplicationsforhumanpluripotentstemcellderivedbloodcomponents AT shijianglu potentialclinicalapplicationsforhumanpluripotentstemcellderivedbloodcomponents |